<SEC-DOCUMENT>0001193125-18-002185.txt : 20180104
<SEC-HEADER>0001193125-18-002185.hdr.sgml : 20180104
<ACCEPTANCE-DATETIME>20180104071432
ACCESSION NUMBER:		0001193125-18-002185
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180104
DATE AS OF CHANGE:		20180104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		18508394

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d509472d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;4, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g509472g0103182852752.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-01011</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">05-0494040</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>One CVS Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Woonsocket, Rhode Island</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>02895</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:&nbsp;(401)
<FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of
this chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the information in Item 7.01 relates to a
completed fiscal period, such information is incorporated by reference into this Item 2.02. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2018, CVS Health Corporation (&#147;CVS Health&#148;)
issued a press release announcing that it is revising its outlook for the fourth quarter of 2017 and providing its full year 2018 guidance. Attached to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> as Exhibit 99.1 is a copy
of CVS Health&#146;s press release dated January&nbsp;4, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in Items 2.02 and 7.01 of this report is being furnished, not filed.
Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by CVS Health under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by
reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>No Offer or Solicitation </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any
securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention
of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Additional Information and Where to Find It </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the proposed transaction between CVS Health and Aetna Inc. (&#147;Aetna&#148;), CVS Health and Aetna will file relevant materials with the Securities and Exchange Commission (the &#147;SEC&#148;), including a CVS Health registration
statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> that will include a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health, and a definitive joint proxy statement/prospectus will be mailed to
stockholders of CVS Health and shareholders of Aetna. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY
WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents
filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health will be available free of charge within the Investors section of CVS Health&#146;s
Web site at http://www.cvshealth.com/investors or by contacting CVS Health&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the documents filed with the
SEC by Aetna will be available free of charge on Aetna&#146;s internet website at http://www.Aetna.com or by contacting Aetna&#146;s Investor Relations Department at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">860-273-8204.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Participants in Solicitation </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies
in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016
(&#147;CVS Health&#146;s Annual Report&#148;), which was filed with the SEC on February&nbsp;9, 2017, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March&nbsp;31, 2017, and its Current Report on
Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which was filed with the SEC on May&nbsp;12, 2017. Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016 (&#147;Aetna&#146;s Annual Report&#148;), which was filed with the SEC on February&nbsp;17, 2017, its proxy statement for its 2017 annual meeting of shareholders,
which was filed with the SEC on April&nbsp;7, 2017, and its Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which were filed with the SEC on May&nbsp;24, 2017 and October&nbsp;2, 2017. Other information regarding the
participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when
they become available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Cautionary Statement Regarding Forward-Looking Statements </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;Reform Act&#148;) provides a safe harbor for forward-looking statements made by or on behalf of
CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as &#147;anticipate,&#148;
&#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;likely,&#148;
&#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the
negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health&#146;s and Aetna&#146;s control.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to
the closing date for the pending acquisition of Aetna (the &#147;transaction&#148;), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of
the transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health&#146;s common stock of CVS Health stockholders and Aetna
shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS
Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies&#146; pharmacy benefit business, the
synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS Health&#146;s and Aetna&#146;s managements&#146; estimates, assumptions and projections, and are
subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and
has not been prepared in conformance with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> relating to pro forma financial information, and the required pro forma adjustments have not been applied and
are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual
future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for
the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be satisfied; the ability to achieve the synergies and
value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking statements regarding CVS Health&#146;s or Aetna&#146;s respective businesses, financial condition
and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS
Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health&#146;s ability to complete the transaction and/or CVS Health&#146;s
ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health&#146;s
ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health&#146;s and Aetna&#146;s respective
filings with the SEC, including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by their Quarterly
Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and future filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on CVS
Health&#146;s and Aetna&#146;s forward-looking statements. These forward-looking statements are and will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as
of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The following exhibits are included with this
report: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated January&nbsp;4, 2018, of CVS Health Corporation.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INDEX TO EXHIBITS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d509472dex991.htm">Press Release, dated January&nbsp;4, 2018, of CVS Health Corporation. </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: January&nbsp;4, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">CVS Health Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David M. Denton</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David M. Denton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President and Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d509472dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g509472g0104062833017.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Provides 2018 Outlook </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Expect Adjusted Consolidated Operating Profit Growth of 1% to 4% </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Enterprise Script Growth and Benefits from Streamlining Initiative Driving Solid Growth </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Fourth Quarter and Full-year 2017 Consolidated Expectations Confirmed </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Fourth Quarter and Full-year 2017 Retail/LTC Expectations Confirmed; </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Pharmacy Services Operating Profit Expectations Lowered </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WOONSOCKET, R.I., January&nbsp;4, 2018 &#150; This morning CVS Health (NYSE: CVS) issued its initial outlook for 2018, expressing confidence in the execution
of its growth strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For full-year 2018, the company expects to deliver consolidated net revenue growth of 0.75% to 2.5% and adjusted consolidated
operating profit growth of 1% to 4%. Adjusted operating profit in its Retail/LTC segment is expected to grow in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits and adjusted operating profit in its Pharmacy Services segment is expected
to grow in the <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single</FONT> digits. Strong growth in scripts and claims, continued purchasing efficiencies from the company&#146;s Red Oak venture, and incremental
net benefits from the company&#146;s streamlining initiative are expected to be beneficial contributors to enterprise growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating profit growth in
2018 is expected to be unfavorably affected by costs associated with the company&#146;s implementation of its contract to provide PBM services to Anthem, Inc. beginning in 2020, as well as the recent divestiture of RxCrossroads. Together, these two
factors reduce expected adjusted consolidated operating profit growth by approximately 125 basis points. While the company continues to expect its pending acquisition of Aetna Inc. to close during the second half of 2018, for guidance purposes only,
the acquisition is assumed to close after <FONT STYLE="white-space:nowrap">year-end</FONT> 2018. As with past acquisitions, all acquisition-related transaction, integration and bridge financing costs will be excluded from the company&#146;s adjusted
figures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Retail/LTC segment, the company expects revenue growth of 2.5% to 4%, driven by strong same store script growth of 6% to 7% primarily as
a result of broader partnerships established with PBMs and health plans and its expanded participation as a preferred pharmacy in a greater number of Medicare Part D networks. The company expects same store sales to be in the range of 2% to 3.5%.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Pharmacy Services segment, the company expects claims growth of approximately 8% and revenue growth of 1.5% to 3.5%. Factors impacting revenue
growth include the administration of rebates for Aetna&#146;s Medicare Part D business, which begins in 2018 under the companies&#146; existing PBM contract; the expectation that generic specialty introductions will increase; the continuation of
brand inflation at levels lower than the market has historically seen; and continuing pricing pressures. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company expects net interest expense in a range of $2.0&nbsp;billion to $2.3&nbsp;billion in 2018. It expects
to use cash on hand to retire debt that will be maturing during the year, but in addition to interest on its existing portfolio of debt, the company will incur acquisition-related bridge financing fees as well as interest on the new debt expected to
be issued to fund the acquisition. The guidance range takes into account the variability of timing of issuance and interest rates as well as the mix of maturities of the new debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company will benefit from the recent comprehensive tax reform signed into law last month. Taking into account the change in the statutory federal rate as
well as the law&#146;s effects on state taxes and other permanent items, the company expects its effective tax rate to be approximately 27% in 2018. This reduction in the tax rate represents an increase in cash flow of approximately
$1.2&nbsp;billion. With the financial flexibility that tax reform provides, the company anticipates making strategic investments in future areas of growth in its business, particularly as CVS Health and Aetna combine to remake the consumer health
experience, and will have more to say as plans are finalized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, the company suspended share repurchases during the fourth quarter
of 2017 due to its pending acquisition of Aetna Inc. Absent the suspension, share repurchases in 2018 would have contributed approximately 340 to 610 basis points of growth to adjusted EPS. The company had also previously announced that it would
maintain its current annual dividend of $2.00 per share throughout the year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the company revised its outlook for the fourth quarter of
2017. Due to softer margin performance in the PBM&#146;s client and retail network claims management process, the company now expects a <FONT STYLE="white-space:nowrap">mid-teens</FONT> growth rate in the fourth quarter and about 4% for the full
year for the Pharmacy Services segment&#146;s adjusted operating profit. The company continues to expect fourth quarter operating profit from its Retail/LTC segment to be at the high end of its previously-provided range of (3.5%) to (1.0%). Combined
with the impact from the suspension of share repurchases, offset by a better effective tax rate, the company expects to deliver adjusted consolidated operating profit growth and adjusted EPS at the lower end of their respective ranges provided
during its third quarter 2017 earnings call. At that time, the company expected adjusted consolidated operating profit growth of 5.75% to 8% and adjusted EPS of $1.88 to $1.92. Also, the company expects to meaningfully benefit in the fourth quarter
from the Tax Cuts and Jobs Act, but estimates of these benefits have not been included as the company is currently assessing the law&#146;s impact on its 2017 financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teleconference and Webcast </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will be holding a
conference call today for the investment community at 11:00 am (ET) to discuss its guidance expectations. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS
Health website at&nbsp;http://investors.cvshealth.com. This webcast will be archived and available on the website for a <FONT STYLE="white-space:nowrap">one-year</FONT> period following the conference call. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health is providing <FONT STYLE="white-space:nowrap">non-GAAP</FONT> information on a prospective basis that excludes certain items because of the nature
of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors&#146; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
understanding of the company&#146;s performance. This information should be considered in addition to, rather than as a substitute for, information prepared in accordance with GAAP. CVS
Health&#146;s definitions of these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> items may not be comparable to similarly-titled measurements reported by other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted earnings per share, or adjusted EPS, is income from continuing operations excluding the impact of certain adjustments such as the amortization of
intangible assets, acquisition-related integration costs, charges in connection with store rationalization, goodwill impairments, adjustments to legal reserves in connection with certain legal settlements, losses on early extinguishment of debt and
losses on settlements of defined benefit pension plans, and the income tax benefit associated with the Tax Reform and Jobs Act included as part of these adjustments for (a)&nbsp;expected EPS for Q4 2017 and 2017 full-year, are amounts related to
bridge financing fees and transaction costs for the proposed acquisition of Aetna, as well as transaction costs for the divestiture of RxCrossroads and (b)&nbsp;adjusted EPS for 2018 guidance, are bridge financing fees and transaction and
integration costs related to the proposed acquisition of Aetna, as well as transaction costs for the divestiture of RxCrossroads. To calculate adjusted EPS, adjusted income from continuing operations is divided by the company&#146;s expected
weighted average diluted shares outstanding for the relevant period. The company believes that this measure enhances investors&#146; ability to compare the company&#146;s past financial performance with its current and expected performance. The most
comparable GAAP measure is diluted earnings per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted operating profit is operating profit excluding the impact of acquisition-related
integration costs, charges in connection with store rationalization, goodwill impairments, and adjustments to legal reserves in connection with certain legal settlements, also included as part of these adjustments for (a)&nbsp;expected adjusted
operating profit for Q4 2017 and 2017 full-year, are amounts related to transaction costs for the proposed acquisition of Aetna, as well as transaction costs for the divestiture of RxCrossroads and (b)&nbsp;adjusted operating profit for 2018
guidance, are transaction and integration costs related to the proposed acquisition of Aetna, as well as transaction costs for the divestiture of RxCrossroads. The company believes that this measure enhances investors&#146; ability to compare the
company&#146;s past financial performance with its current expected performance. The most comparable GAAP measure is operating profit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As there is
uncertainty in connection with calculating the adjustments necessary to prepare reconciliations from the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures to the comparable GAAP financial measures, the company is unable to
reconcile the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures without unreasonable efforts. The items, including, in particular, the additional excluded items identified above, could result in significant adjustments from the
most comparable GAAP measure. In addition, for the 2018 guidance estimates of adjusted EPS and adjusted operating profit, the significant complexity in assessing the impact of tax reform changes creates additional challenges in providing
reconciliations to the most comparable GAAP measures. Therefore, no reconciliation is being provided at this time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,700 retail locations, more than 1,100 <FONT
STYLE="white-space:nowrap">walk-in</FONT> medical clinics, a leading pharmacy benefits manager with nearly 90&nbsp;million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty
pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to
quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at&nbsp;https://www.cvshealth.com. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;Reform Act&#148;) provides a safe harbor for forward-looking statements made by or on behalf of
CVS Health or Aetna.&nbsp;This communication may contain forward-looking&nbsp;statements within the meaning of the Reform Act. You can generally identify&nbsp;forward-looking&nbsp;statements by the use of&nbsp;forward-looking terminology such as
&#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148; &#147;guidance,&#148;
&#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148;
&#147;view,&#148; or &#147;will,&#148; or the negative thereof or other variations thereon or comparable terminology. These&nbsp;forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are
beyond CVS Health&#146;s and Aetna&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this communication regarding CVS Health and Aetna that are forward-looking, including
CVS Health&#146;s and Aetna&#146;s projections as to the closing date for the pending acquisition of Aetna (the &#147;transaction&#148;), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the
anticipated benefits of the transaction, the impact of the transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health&#146;s
common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations regarding debt repayment and its debt to capital
ratio following the closing of the transaction, CVS Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined
companies&#146; pharmacy benefit business, the synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS Health&#146;s and Aetna&#146;s managements&#146;
estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is
based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> relating to pro forma financial information, and the
required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk
factors related to the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to:&nbsp;the timing to consummate the proposed transaction;
the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may
not be satisfied; the ability to achieve the synergies and value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of and attention of management of both CVS Health and
Aetna on transaction-related issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking statements regarding CVS Health&#146;s or Aetna&#146;s
respective businesses, financial condition and results of operations.&nbsp;These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently
believe to be immaterial also may cause CVS Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health&#146;s ability to complete
the transaction and/or CVS Health&#146;s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or
CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the transaction and/or realize the expected benefits from the transaction.&nbsp;Additional information concerning these risks, uncertainties and assumptions can be found in CVS
Health&#146;s and Aetna&#146;s respective filings with the Securities and Exchange Commission (the &#147;SEC&#148;), including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual
Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> as updated by their Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and future filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on CVS Health&#146;s and Aetna&#146;s forward-looking statements.&nbsp;These forward-looking statements are and
will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements.&nbsp;Neither CVS Health nor Aetna assumes any duty to update or
revise forward-looking&nbsp;statements, whether as a result of new information, future events or otherwise, as of any future date. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of
an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall
there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of
1933, as amended, and otherwise in accordance with applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction between CVS Health and Aetna, CVS Health and Aetna will file relevant materials with the SEC, including a CVS
Health registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> that will include a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health, and a definitive joint proxy statement/prospectus
will be mailed to stockholders of CVS Health and shareholders of Aetna. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND
IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available)
and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by CVS Health will be available free of charge within the Investors section of
CVS Health&#146;s Web site at http://www.cvshealth.com/investors or by contacting CVS Health&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the
documents filed with the SEC by Aetna will be available free of charge on Aetna&#146;s internet website at http://www.Aetna.com or by contacting Aetna&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">860-273-8204.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies
in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016
(&#147;CVS Health&#146;s Annual Report&#148;), which was filed with the SEC on February&nbsp;9, 2017, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March&nbsp;31, 2017, and its Current Report on
Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which was filed with the SEC on May&nbsp;12, 2017. Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016 (&#147;Aetna&#146;s Annual Report&#148;), which was filed with the SEC on February&nbsp;17, 2017, its proxy statement for its 2017 annual meeting of shareholders,
which was filed with the SEC on April&nbsp;7, 2017 and its Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which were filed with the SEC on May&nbsp;24, 2017 and October&nbsp;2, 2017. Other information regarding the participants
in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become
available. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g509472g0103182852752.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509472g0103182852752.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P )D# 2(  A$! Q$!_\0
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; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g509472g0104062833017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g509472g0104062833017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 0H# 2(  A$! Q$!_\0
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M*[>@ HHHH **** "BBOG_P =W/C#PCXXTE/^$KNIK/4KU2L"G C0R ;?R.*
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
